Leustatin Related Published Studies
Well-designed clinical trials related to Leustatin (Cladribine)
Cladribine alone and in combination with cyclophosphamide or cyclophosphamide plus mitoxantrone in the treatment of progressive chronic lymphocytic leukemia: report of a prospective, multicenter, randomized trial of the Polish Adult Leukemia Group (PALG CLL2). [2006.07.15]
Cladribine for multiple sclerosis: review and current status. [2005.11]
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). [2005.10]
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study. [2004.05]
Increased remissions from one course for intermediate-dose cytosine arabinoside and idarubicin in elderly acute myeloid leukaemia when combined with cladribine. A randomized population-based phase II study. [2003.12]
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. [2002.10.15]
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. [2001.10]
Effect of immunosuppressive cladribine treatment on serum leucocytes system in two-year clinical trial in patients with chronic progressive multiple sclerosis. [2001.01]
Whole brain volume changes in patients with progressive MS treated with cladribine. [2000.12.12]
Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial. [2000.10.15]
The effect of cladribine on T(1) 'black hole' changes in progressive MS. [2000.05.01]
Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. [2000.03.14]
The cladribine trial in secondary progressive multiple sclerosis: A reanalysis. [2000.03]
Fludarabine and cladribine in relapsed/refractory low-grade non-Hodgkin's lymphoma: a phase II randomized study. [2000.02]
Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients. [2000.02]
A double-blind, placebo-controlled, randomized trial of cladribine in relapsing-remitting multiple sclerosis. [1999.01]
[Chronic lymphatic leukemia. Peroral cladribine as primary treatment] [1996.11.04]
Development of cladribine treatment in multiple sclerosis. [1996.07]
The treatment of chronic progressive multiple sclerosis with cladribine. [1996.02.20]
Cladribine in treatment of chronic progressive multiple sclerosis. [1994.07.02]
Well-designed clinical trials possibly related to Leustatin (Cladribine)
Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis. [2006.08]
Asymmetries in the spatial distributions of enhancing lesions and black holes in relapsing-remitting MS. [2005.11]
New hypointense lesions on MRI in relapsing-remitting multiple sclerosis patients. [2000]
Responsiveness of the Scripps neurologic rating scale during a multiple sclerosis clinical trial. [1999.11]
Hypointense and hyperintense lesions on magnetic resonance imaging in secondary-progressive MS patients. [1999.07]
2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia. [1998.01]
A comparison of two neurologic scoring instruments for multiple sclerosis. [1996.03]
The value of magnetic resonance imaging in diagnosis and monitoring of treatment in multiple sclerosis. [1996]
The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. [1994]
Treatment of hairy-cell leukemia. [1990.12]
Other research related to Leustatin (Cladribine)
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. [2008.07.15]
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. [2008.07.01]
Randomized comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients: final report of the Polish Lymphoma Research Group. [2008.05.09]
Cladribine in indolent non-Hodgkin's lymphoma. [2008.04]
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group. [2008.02]
Combined treatment with splenectomy and cladribine in hairy cell leukemia in Taiwan: a clinicopathologic study of 5 cases. [2007.12]
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. [2007.11.15]
[Successful use of cladribine in the treatment of an elderly woman with typical hairy cell leukemia] [2007.11]
The potential role for cladribine in the treatment of multiple sclerosis: clinical experience and development of an oral tablet formulation. [2007.11]
[Combination therapy with rituximab and cladribine for patients with follicular lymphoma] [2007.10]
Rituximab plus cladribine with or without cyclophosphamide in patients with relapsed or refractory chronic lymphocytic leukemia. [2007.08]
Chromosomal translocations independently predict treatment failure, treatment-free survival and overall survival in B-cell chronic lymphocytic leukemia patients treated with cladribine. [2007.08]
Cladribine in aggressive forms of multiple sclerosis. [2007.06]
Cladribine combined with cyclophosphamide and mitoxantrone is an active salvage therapy in advanced non-Hodgkin's lymphoma. [2007.06]
Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. [2007.05.01]
[Treatment of hairy cell leukemia with cladribine] [2007.03]
Fludarabine vs cladribine plus busulfan and low-dose TBI as reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation: a prospective randomized trial. [2007.02]
Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. [2007.01.05]
The multicenter trial SAKK 37/95 of cladribine, cyclophosphamide and prednisone in the treatment of chronic lymphocytic leukemias and low-grade non-Hodgkin's lymphomas. [2007]
In vitro sensitivity of B-cell chronic lymphocytic leukemia to cladribine and its combinations with mafosfamide and/or mitoxantrone. [2006.12]
Cladribine therapy in refractory celiac disease with aberrant T cells. [2006.11]
Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma. [2006.10.01]
[Successful salvage therapy with cladribine and rituximab for a patient with a relapsed Asian variant of intravascular large B-cell lymphoma] [2006.10]
Cladribine in hairy cell leukemia. [2006.10]
Cladribine: an investigational immunomodulatory agent for multiple sclerosis. [2006.10]
[Pulmonary cryptococcosis occurring 6 months after cladribine therapy for relapsed follicular lymphoma] [2006.07]
Potential predictive patterns of minimal residual disease detected by immunohistochemistry on bone marrow biopsy specimens during a long-term follow-up in patients treated with cladribine for hairy cell leukemia. [2006.03]
Transformation and progression of Waldenstrom's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation? [2006.02]
PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. [2006.01.15]
Early-onset autoimmune hemolytic anemia after cladribine therapy for Waldenstrom's macroglobulinemia. [2006.01]
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients. [2005.12]
[Successful treatment with cladribine for hypoplastic hairy cell leukemia after long-term neutropenia] [2005.11]
Phase II clinical study of cladribine in the treatment of hairy cell leukemia. [2005.10]
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group. [2005.09]
Activity of cladribine combined with etoposide in heavily pretreated patients with indolent lymphoid malignancies. [2005.08]
Application of population pharmacokinetics to cladribine. [2005.03.09]
Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. [2005.03]
The place of cladribine in the treatment of chronic lymphocytic leukemia: a 10-year experience in Poland. [2005.02]
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases. [2004.12]
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study. [2004.10]
Acute myeloid leukemia following treatment with cladribine for hairy cell leukemia: a case report and review of the literature. [2004.10]
Cladribine: from the bench to the bedside--focus on hairy cell leukemia. [2004.10]
[Cladribine monotherapy for patients with relapsed or refractory indolent non-Hodgkin lymphoma] [2004.07]
T(11;18)-bearing pulmonary mucosa-associated lymphoid tissue lymphoma responding to cladribine. [2004.07]
[Hairy cell leukemia therapy by cladribine] [2004.07]
["Smoldering systemic mastocytosis. "Successful therapy with cladribine] [2004.07]
Efficacy of continuous infusion 2-CDA (cladribine) in pediatric patients with Langerhans cell histiocytosis. [2004.07]
Metabolic response patterns of nucleotides in B-cell chronic lymphocytic leukaemias to cladribine, fludarabine and deoxycoformycin. [2004.07]
Metabolism of the antineoplastic and immunosuppressive drug 2-CdA (Leustatin) in animals and humans. [2004.06]
[Successful induction and complete improvement of myelofibrosis and erythema nosodum with cladribine in a case of hairy cell leukemia] [2004.06]
Interleukin-8 and RANTES levels in patients with relapsing-remitting multiple sclerosis (RR-MS) treated with cladribine. [2004.06]
Epstein-Barr virus positive large B-cell lymphoma arising in a patient previously treated with Cladribine for hairy cell leukemia. [2004.05]
Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. [2004.05]
Treatment of indolent non-Hodgkin's lymphoma with cladribine as single-agent therapy and in combination with mitoxantrone. [2004.05]
[Hairy cell leukemia, Japanese variant, successfully treated with cladribine] [2004.05]
Phase II trial of cladribine and cytarabine in relapsed or refractory myeloid malignancies. [2004.04]
Determination of the in vivo effects of cladribine alone and its combination with cyclophosphamide or cyclophosphamide and mitoxantrone on Bax and Bcl-2 protein expression in B-CLL cells. [2004.03]
Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. [2004.02]
Successful pregnancy after cladribine therapy for hairy cell leukemia. [2004.01]
Cladribine followed by autologous stem-cell transplantation in progressive multiple sclerosis. [2004.01]
Cladribine therapy for systemic mastocytosis. [2003.12.15]
Immune reconstitution following reduced-intensity transplantation with cladribine, busulfan, and antithymocyte globulin: serial comparison with conventional myeloablative transplantation. [2003.09]
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG). [2003.09]
Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. [2003.08.01]
Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma. [2003.06]
Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide. [2003.05]
Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. [2003.03.01]
Cladribine in the treatment of hairy-cell leukaemia. [2003.03]
Comparison of cytotoxicity of 2-chloro- 2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia. [2003.03]
[Cladribine] [2003.02]
A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. [2003.02]
|
